Skip to main content

ARQT

Stock
Health Care
Biotechnology

Performance overview

ARQT Price
Price Chart

Forward-looking statistics

Beta
1.28
Risk
77.03%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Company info

SectorHealth Care
IndustryBiotechnology
Employees282
Market cap$838.1M

Fundamentals

Enterprise value$1.6B
Revenue$212.8M
Revenue per employee—
Profit margin-60.95%
Debt to equity77.67

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.04
Dividend per share—
Revenue per share$1.71
Avg trading volume (30 day)$31M
Avg trading volume (10 day)$30M
Put-call ratio—

Macro factor sensitivity

Growth+21.3
Credit+32.6
Liquidity-30.4
Inflation+13.8
Commodities+6.5
Interest Rates-1.8

Valuation

Dividend yield0.00%
PEG Ratio-14.10
Price to sales7.74
P/E Ratio-14.10
Enterprise Value to Revenue7.44
Price to book11.55

Upcoming events

Next earnings dayNovember 7, 2024
Next dividend day—
Ex. dividend day—

News

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates

Arcutis Biotherapeutics, Inc. (ARQT) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.32 per share a year ago.

Zacks Investment Research (May 6, 2025)
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs

As of March 25, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Benzinga (March 25, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free